TANGO THERAPEUTICS IN

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

21 مايو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

12 مايو 2025 04:00:01 بحسب Nasdaq GlobeNewswire

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

01 مايو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

25 مارس 2025 13:30:00 بحسب Nasdaq GlobeNewswire

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights 

27 فبراير 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences

20 فبراير 2025 04:30:00 بحسب Nasdaq GlobeNewswire

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

30 يناير 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024

05 مارس 2024 13:47:49 بحسب Nasdaq GlobeNewswire

Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

31 يناير 2024 04:00:00 بحسب Nasdaq GlobeNewswire

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 يناير 2024 13:05:00 بحسب Nasdaq GlobeNewswire

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers

03 يناير 2024 04:00:00 بحسب Nasdaq GlobeNewswire

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

13 نوفمبر 2023 04:00:00 بحسب Nasdaq GlobeNewswire

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

08 نوفمبر 2023 04:00:01 بحسب Nasdaq GlobeNewswire

Tango Therapeutics to Present at the Jefferies London Healthcare Conference

07 نوفمبر 2023 04:00:00 بحسب Nasdaq GlobeNewswire

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

18 سبتمبر 2023 04:00:00 بحسب Nasdaq GlobeNewswire

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers

06 سبتمبر 2023 04:00:00 بحسب Nasdaq GlobeNewswire

Tango Therapeutics Announces Updates to Its Board of Directors

29 أغسطس 2023 14:08:05 بحسب Nasdaq GlobeNewswire

Tango Therapeutics Announces $80 million Private Placement Financing

10 أغسطس 2023 04:00:19 بحسب Nasdaq GlobeNewswire

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

07 أغسطس 2023 04:00:00 بحسب Nasdaq GlobeNewswire

Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

10 يوليو 2023 04:00:00 بحسب Nasdaq GlobeNewswire